Member Info for Bella6532

Wouldn't want Zeus anywhere near...

There's your buy and sell...so yes there was some serious order filling yesterday...

24-Oct-24 17:05:26 59.00 888,732 Unknown* 524.35k O

24-Oct-24 16:28:30 61.00 811,268 Unknown* 494.87k O

24-Oct-24 16:47:05 62.82353 170,000 Buy* 106.80k O

24-Oct-24 16:37:39 58.57833 150,000 Buy* 87.

And it was in P3...wasn't it?

Worth repeating...."Potent topoisomerase I inhibitors are the payloads of ADC therapies in the clinic, although the non-specific release of these payloads can lead to severe off-target toxicities. Given the lack of these toxicities in our first program and the broad reach of the topoisomerase I inhibitor class, we see our next programs as having great potential for true impact in patients with high unmet need."

...with x dosage increase and potentially no/limited side effects...kill...kill...kill those pesky cancer cells...

Big Investor Funding/licence Deal

NASDAQ move...application or RTO

T/O

FDA Approval

More Pipeline Reveals

????

'AffDCs have an antigen-binding region of 14kDa (single-domain) or 28 kDa (two-domain) that is 10-20% of the size of an antibody, optimizing tumor penetration. '

Get in there!!!...

Wow...what results...kill kill kill...a word used several times which hasn't been the case before I don't think.

Targetting to Killing...that's quite a move in emphasis isn't it...?

75 times standard dose of a wicked drug...wow...

A bit more about Tempus...

'June 5 (Reuters) - Tempus AI, backed by Japanese tech investment firm SoftBank Group, is targeting a valuation of up to $6.10 billion for its U.S. initial public offering, nearly three years after the genetics-testing company laid the ground for its listing.

The listing of the company, which is led by e-commerce marketplace Groupon (GRPN.O)co-founder Eric Lefkofsky and is yet to be profitable, will test investor appetite.

Tempus, which confidentially filed for an IPO in September 2021, is aiming to raise as much as $410.7 million by selling 11.1 million shares at a price range of $35 to $37.

Chicago, Illinois-based Tempus' net loss widened to $289.8 million in 2023 from $214.1 million a year earlier, while total revenue jumped 65.8% to $531.8 million.

The company was founded in 2015, about a year after Lefkofsky's wife was diagnosed with breast cancer. Tempus sells genomics diagnostics tests across oncology and other areas, including neuropsychiatry, radiology, and cardiology to clinicians and hospital systems.'

'Workings are very simple AVA6000 can be given for many more cycles than standard treatment hence the patients will LIKELY live longer and PFS would kick in. '

And in the real world treatment would start far sooner not at the end of life stage...

Tempus Road Show Clips June 24

https://youtube.com/watch?v=XLO8kPcMXJk&si=1ujetI1G41AK6IDS

'Professor Jones is a medical oncologist specialising in the treatment of bone and soft tissue sarcomas and Head of the Sarcoma Unit at The Royal Marsden.'

'William D. Tap, MD is the Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York. He is a medical oncologist who specializes in the treatment of patients with soft tissue and bone sarcomas.'

'Advanced hormone-refractory prostate cancer (HRPC) is characterized by prevalently osteoblastic bone metastases which are what mostly affect these patients' quality of life and make the assessment of response to treatment particularly difficult by commonly used criteria. HRPC cannot be cured by any available therapeutic option, and chemotherapy has to be still considered as a palliative treatment. The anthracyclines doxorubicin (Dox) and epirubicin (Epi), alone or in combination with other agents, have been extensively used in the treatment of HRPC, but controversial results have been reported. The majority of reviewed studies reported a pain reduction in >50% of patients receiving Dox or Epi, suggesting a substantial palliative effect by their use in metastatic HRPC. The weekly schedule of anthracyclines seemed to achieve similar results to the 3-weekly schedule but with a better toxicity profile. Although the toxic adverse effects were usually manageable when anthracyclines were combined with other agents, toxicity was severe by a number of aggressive regimens.'

My comment was made to open up discussion regarding how cancer in the bone environment can be FAP high but tends to be the most difficult to treat and therefore leads to a terminal assessment.

NOTE TO AVACTA...If you are reading this, please contact Chris Hoy...

Https://www.share-talk.com/avacta-the-british-biotech-disrupting-cancer-treatment/

Why do these articles all sound like they are written by chat bot thingies...too researched for a human to have wrtten but still contains big gaffs...

'Direct question. Why pay in cash last time and now in stock?'....because they can..they have the choice.

? TG's last day today (Friday)

RNS today at 7am announcing PF as new CFO? Who is

also another link to Eliot Forster.

Will this be the last Board change jigsaw piece prior to Investor announcement...?

Hey Timster...sorry to hear about your SIL...chemo is wicked...I saw what it did to my husband who had to undergo 2 lots each being 14 sessions every 2 weeks...he still has issues left by the damage it did to none affected tissues.

If we can't find a cure, then Chemo without the horrendous side effects/damage would definitely be a blessing for many and hopefully a way of also administering higher doses for shorter periods.

Bring it on Avacta....now let's get the funding sorted...

So AVCT do you know for sure what lead to the midday rise today...no assumptions please...just fact...thanks